AZD9291 is an irreversible, mutant specific EGFR tyrosine kinase inhibitor. It is effective in pre-clinical tumor models and clinical trials in patients with TKI sensitizing and T790M resistant tumors. It is generally well tolerated. Activating mutations within the epidermal growth factor receptor (EGFR) mutations are present in approximately 20% of all lung adenocarcinomas. EGFR -mutant cancers are dependent on EGFR signaling for growth and survival, making inhibition of EGFR an attractive therapeutic target.
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.